A Phase I study of irinotecan, bevacizumab and TAS-102 for metastatic colorectal cancer patients

ABSTRACT: Interventions: Medication Primary outcome(s): Dose limiting toxicity Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Unresectable Metastatic Colorectal Cancer

PROVIDER: 2614802 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR